| scholarly article | Q13442814 |
| P50 | author | Klaus Olkkola | Q38804752 |
| Pertti J. Neuvonen | Q23039874 | ||
| P2093 | author name string | Kari Laine | |
| Ville V Hynninen | |||
| P2860 | cites work | Development and validation of a high-performance liquid chromatography assay for voriconazole | Q39776152 |
| Analysis of OSPAR priority pharmaceuticals using high-performance liquid chromatography-electrospray ionisation tandem mass spectrometry | Q41944488 | ||
| Voriconazole potentiates warfarin‐induced prothrombin time prolongation | Q42029509 | ||
| Characterization of etoricoxib, a novel, selective COX-2 inhibitor | Q44484802 | ||
| Miconazole oral gel and drug interactions | Q44886991 | ||
| The effects of modifying in vivo cytochrome P450 3A (CYP3A) activity on etoricoxib pharmacokinetics and of etoricoxib administration on CYP3A activity. | Q45040968 | ||
| Inhibition of cytochromes P450 by antifungal imidazole derivatives | Q45712828 | ||
| Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes | Q46686355 | ||
| Effect of antifungal drugs on cytochrome P450 (CYP) 1A2, CYP2D6, and CYP2E1 activities in human liver microsomes | Q46686360 | ||
| Voriconazole, but not terbinafine, markedly reduces alfentanil clearance and prolongs its half-life | Q48642908 | ||
| Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam | Q48710479 | ||
| Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction. | Q52933446 | ||
| Mechanisms of the stereoselective interaction between miconazole and racemic warfarin in human subjects | Q68167898 | ||
| A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors | Q71757419 | ||
| Rapid method for the analysis of itraconazole and hydroxyitraconazole in serum by high-performance liquid chromatography | Q73032564 | ||
| Miconazole oral gel potentiates warfarin anticoagulant activity | Q73818115 | ||
| A rapid HPLC assay for voriconazole in human plasma | Q77506371 | ||
| Determination of rofecoxib (MK-0966), a cyclooxygenase-2 inhibitor, in human plasma by high-performance liquid chromatography with tandem mass spectrometric detection | Q33422555 | ||
| Single- and multiple-dose pharmacokinetics of etoricoxib, a selective inhibitor of cyclooxygenase-2, in man. | Q34183755 | ||
| Role of human liver cytochrome P4503A in the metabolism of etoricoxib, a novel cyclooxygenase-2 selective inhibitor | Q34515171 | ||
| Absorption, metabolism, and excretion of etoricoxib, a potent and selective cyclooxygenase-2 inhibitor, in healthy male volunteers | Q34530443 | ||
| Renal effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs in controlled clinical trials | Q35680546 | ||
| Potentiation of warfarin anticoagulant activity by miconazole oral gel. | Q36242660 | ||
| Pharmacokinetic/pharmacodynamic profile of voriconazole | Q36520587 | ||
| P433 | issue | 1 | |
| P921 | main subject | pharmacokinetics | Q323936 |
| voriconazole | Q412236 | ||
| pharmacodynamics | Q725307 | ||
| P304 | page(s) | 89-95 | |
| P577 | publication date | 2008-09-09 | |
| P1433 | published in | European Journal of Clinical Pharmacology | Q1376707 |
| P1476 | title | Oral voriconazole and miconazole oral gel produce comparable effects on the pharmacokinetics and pharmacodynamics of etoricoxib | |
| P478 | volume | 65 |
| Q34847583 | Clinical pharmacokinetic and pharmacodynamic profile of etoricoxib |
| Q24317436 | Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3A |
| Q34610283 | Etoricoxib: a review of its use in the symptomatic treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute gouty arthritis |
| Q33681207 | Influence of processing parameters and formulation factors on the bioadhesive, temperature stability and drug release properties of hot-melt extruded films containing miconazole |
| Q34737242 | Miconazole oral gel increases exposure to oral oxycodone by inhibition of CYP2D6 and CYP3A4. |
| Q46703325 | Serotonin syndrome during treatment with low dose of escitalopram associated with miconazole mucoadhesive tablet: a suspected drug interaction |
Search more.